- Serum lipocalin-2 is a potential biomarker for the clinical diagnosis of nonalcoholic steatohepatitis
-
Xu G, Wang YM, Ying MM, Chen SD, Li ZR, Ma HL, Zheng MH, Wu J, Ding C
- KMID: 2514774
- Clin Mol Hepatol.
- 2021 Apr;27(2):329-345.
- doi: 10.3350/cmh.2020.0261
Background/Aims: Nonalcoholic steatohepatitis (NASH) is a progressive form of nonalcoholic fatty liver disease (NAFLD) characterized by hepatic steatosis, inflammation, hepatocellular injury, and fibrosis. We aimed to investigate the usefulness of... -
- CITED
-
- Close
- SHARE
-
- Close
- Protective association of Klotho rs495392 gene polymorphism against hepatic steatosis in non-alcoholic fatty liver disease patients
-
Liu WY, Zhang X, Li G, Tang LJ, Zhu PW, Rios RS, Zheng KI, Ma HL, Wang XD, Pan Q, de Knegt RJ, Valenti L, Ghanbari M, Zheng MH
- KMID: 2528248
- Clin Mol Hepatol.
- 2022 Apr;28(2):183-195.
- doi: 10.3350/cmh.2021.0301
Background/Aims: Non-alcoholic fatty liver disease (NAFLD) is closely associated with metabolic dysfunction. Among the multiple factors, genetic variation acts as important modifiers. Klotho, an enzyme encoded by the klotho (KL)... -
- CITED
-
- Close
- SHARE
-
- Close
